^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Northstar Select™

Company:
BillionToOne
Type:
Laboratory Developed Test
Related tests:
Evidence

News

29d
Clinical • Liquid biopsy • Biopsy
|
Northstar Select™
2ms
Culmination Bio partners with BillionToOne to drive diagnostic solutions in oncology (Webwire)
"Culmination Bio...announced a partnership with BillionToOne, Inc. Culmination Bio and BillionToOne are working together to leverage their respective strengths in order to facilitate the development and validation of robust and impactful oncology diagnostics."
Licensing / partnership
|
Northstar Response™ • Northstar Select™
3ms
Analytical and clinical validity of Northstar Select, a quantitatively enhanced liquid biopsy assay for comprehensive genomic profiling of solid tumors (AACR 2024)
These results demonstrate that the Northstar Select assay is an innovative and high-performing diagnostic for treatment selection in oncology, leveraging quantitative approaches in process design, chemistry, and bioinformatics to offer superior analytical and clinical performance compared to the current landscape of liquid biopsy CGP tests.
Clinical • Liquid biopsy • Biopsy
|
Northstar Select™
over1year
BillionToOne appoints Dr. Gary Palmer as Chief Medical Officer, Oncology; launches Northstar Select™ and Northstar Response™ Liquid Biopsy Assays for commercial use (BillionToOne Press Release)
"BillionToOne...is excited to announce...the launch of its Northstar liquid biopsy assays for commercial use...The Northstar liquid biopsy assays are available now for patients with late stage (III/IV) solid tumors. They have been uniquely developed to work together. Northstar Select is an 81-gene next generation sequencing (NGS)-based panel to guide therapy selection...Northstar Response is designed to help clinicians understand if a patient is responding to therapy."
Launch
|
Northstar Response™ • Northstar Select™
almost2years
BillionToOne launches oncology liquid biopsy products for research use & announces clinical research collaboration with UCSD (PRNewswire)
"BillionToOne, Inc...announces the launch of its first oncology liquid biopsy products, Northstar Select™ and Northstar Response™....Today, BillionToOne also announced that it has entered a research collaboration partnership with University of California, San Diego (UCSD). Northstar Select and Northstar Response will be evaluated using late-stage non-small cell lung cancer (NSCLC) patient samples....BillionToOne is conducting additional clinical studies with other academic cancer centers on different cancer types and is expected to launch the commercial versions of Northstar Select and Northstar Response for clinical use in Q1 2023."
Licensing / partnership • Launch
|
Northstar Response™ • Northstar Select™